Castration-refractory prostate cancer: New drugs in the pipeline
- First Online:
- Cite this article as:
- Schrijvers, D., Van Erps, P. & Cortvriend, J. Adv Therapy (2010) 27: 285. doi:10.1007/s12325-010-0038-1
- 72 Downloads
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.